#USA #Washington, D.C. #Target RWE #causal inference #ISPE 2025

Target RWE at ISPE 2025: Powering Evidence Generation with Causal Inference

Target RWE, a pioneering organization in modern evidence generation, has announced its participation in the upcoming ISPE Annual Conference 2025, scheduled to be held in Washington, D.C. on August 21, 2025. This event will mark a significant platform for the company to present their latest findings and methodologies pertaining to complex clinical and regulatory challenges, particularly focusing on causal inference and data-agnostic approaches.

Innovative Presentations and Insights

At the heart of Target RWE's presentation at the ISPE conference will be a series of three pivotal abstracts showcasing the company's commitment to methodological rigor and real-world significance. The sessions will provide valuable insights into the integration of real-world data (RWD) with randomized controlled trials (RCTs)—a critical area that bridges traditional clinical research with modern data-centric approaches to evidence generation.

Symposium Presentation

The symposium will feature an insightful presentation titled "Integrating Real-World Data with Randomized Controlled Trials: Advancing Evidence Generation" led by Dr. Jennifer Christian, the Chief Scientific Officer at Target RWE. This session is set to explore practical strategies for merging RWD with traditional RCTs, providing a robust framework for enhancing the evidentiary base required for regulatory and research purposes. The presentation will delve into case studies from various therapeutic areas like oncology and cardiovascular interventions, where integrating real-world insights has proven essential. Participants will gain valuable lessons on creating external control arms and ensuring both the relevance and reliability of data integration, ultimately aiming to extend trial results to broader patient populations.

Poster Presentations

In addition to the symposium, two insightful poster presentations will unfold:
1. Estimating Artificial Censoring Weights for Clone Censor Weighting Studies: Techniques and Lessons Learned presented by Dr. David Pritchard. This poster will highlight practical methods for implementing clone censor weighting (CCW), which estimates counterfactual outcomes while addressing inherent challenges like immortal time bias. A focus will be placed on the vital task of estimating artificial censoring weights, which are critical for reweighting adherent patients in treatment protocols.
2. Power vs. Precision When Estimating Risk Differences Using Observational Data: A Case Study from TARGET-IBD presented by Dr. Yasmmyn Salinas. This presentation tackles the complexities associated with traditional sample size techniques in observational studies where participant numbers are fixed but confounding factors exist. Leveraging data from Target RWE's inflammatory bowel disease (IBD) cohort, it aims to contrast estimates of power and precision regarding the risk difference in surgical or hospitalization events among differing patient response levels to treatment.

These presentations underscore Target RWE’s dedication to closing evidence gaps using advanced analytics to address complex treatment and policy inquiries. Their innovative approach promotes impactful, high-quality insights essential for the evolving landscape of pharmacoepidemiology.

A Reliable Partner in Evidence Generation

Target RWE is not only a leader in evidence generation but is also renowned for its focus on causal inference methodologies—a foundational strength with dedicated teams of skilled epidemiologists and statisticians. These experts collaborate with clinical research teams, making complex methodologies more practical and accessible, thereby translating advanced techniques into actionable insights that influence drug development decisions.

One of the key innovations from Target RWE is causalStudio™, a proprietary platform designed to facilitate the application of causal inference for real-world use. This platform allows researchers to simulate trial-like conditions, align on estimands, and produce reliable outputs that can withstand regulatory scrutiny.

Equipped with a robust, data-agnostic infrastructure and custom analytics consulting services, Target RWE empowers clients to answer critical health questions with clarity and confidence.

Shaping the Future of Pharmacoepidemiology

In the words of Dr. Jennifer Christian, "Target RWE is dedicated to enabling our partners to generate top-quality, real-world evidence for regulatory filings, health technology assessments, or scientific publications." The company looks forward to its robust presence at the ISPE 2025 conference, reflecting its ongoing commitment to collaboration, innovation, and excellence in science.

As the field of pharmacoepidemiology continues to converge with regulatory science, Target RWE remains a vanguard not only in providing data but also in guiding the direction for future research initiatives. For additional details about their custom analytics, causal inference capabilities, or collaborative research services, interested parties are encouraged to visit targetrwe.com or reach out via email.